Pharsight

Acorda patents expiration

1. Inbrija patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7384649 ACORDA Particulate compositions for pulmonary delivery
Nov, 2022

(10 months ago)

US9155699 ACORDA Pulmonary delivery for levodopa
Mar, 2023

(6 months ago)

US8404276 ACORDA Pulmonary delivery for levodopa
Mar, 2023

(6 months ago)

US8586093 ACORDA Pulmonary delivery for levodopa
Mar, 2023

(6 months ago)

US7182961 ACORDA Particulate compositions for pulmonary delivery
Feb, 2024

(4 months from now)

USRE43711 ACORDA Pulmonary delivery for levodopa
Feb, 2029

(5 years from now)

US8945612 ACORDA Capsules containing high doses of levodopa for pulmonary use
Nov, 2032

(9 years from now)

US8685442 ACORDA Capsules containing high doses of levodopa for pulmonary use
Nov, 2032

(9 years from now)

US9393210 ACORDA Capsules containing high doses of levodopa for pulmonary use
Nov, 2032

(9 years from now)

US8545878 ACORDA Capsules containing high doses of levodopa for pulmonary use
Nov, 2032

(9 years from now)

Drugs and Companies using LEVODOPA ingredient

Market Authorisation Date: 21 December, 2018

Treatment: Intermittent treatment of off episodes in patients with parkinson's disease treated with carbidopa/levodopa by inhalation of levodopa powder particles

Dosage: POWDER;INHALATION

More Information on Dosage

INBRIJA family patents

Family Patents

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic